A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.

IMC001 - Immunofoco

tolododekin alfa (ANK-101) - Ankyra Therap

Libtayo (cemiplimab-rwlc) - Regeneron

Jong Chul Park; Marcus Butler; Brendan Curti; Gail Iodice; Danielle Pastor; Joseph Elassal; Howard Kaufman; John Kirkwood

Apr 23, 2025